PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
M He, C Cao, Z Ni, Y Liu, P Song, S Hao, Y He… - … and Targeted Therapy, 2022 - nature.com
Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
X Li, W Pu, Q Zheng, M Ai, S Chen, Y Peng - Molecular cancer, 2022 - Springer
Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …
Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives
R Jenke, N Reßing, FK Hansen, A Aigner, T Büch - Cancers, 2021 - mdpi.com
Simple Summary Beyond mutations, epigenetic changes have been described as drivers for
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …
A bibliometric analysis of PROTAC from 2001 to 2021
D Li, D Yu, Y Li, R Yang - European journal of medicinal chemistry, 2022 - Elsevier
Proteolysis targeting chimera (PROTAC) technology, one of the targeted protein degradation
technologies, has drawn marked attention from researchers of both academia and industry …
technologies, has drawn marked attention from researchers of both academia and industry …
Targeted protein degradation: advances in drug discovery and clinical practice
G Zhong, X Chang, W **e, X Zhou - Signal Transduction and Targeted …, 2024 - nature.com
Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in
disease management, providing a stark contrast to traditional therapeutic approaches like …
disease management, providing a stark contrast to traditional therapeutic approaches like …
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
Epigentic enzymes histone deacetylases (HDACs) catalyze the removal of acetyl groups
from the ε-N-acetylated lysine residues of various protein substrates including both histone …
from the ε-N-acetylated lysine residues of various protein substrates including both histone …
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
Targeted protein degradation refers to the use of small molecules that recruit a ubiquitin
ligase to a target protein for ubiquitination and subsequent proteasome-dependent …
ligase to a target protein for ubiquitination and subsequent proteasome-dependent …
HDAC inhibitors: innovative strategies for their design and applications
M Daśko, B de Pascual-Teresa, I Ortín, A Ramos - Molecules, 2022 - mdpi.com
Histone deacetylases (HDACs) are a large family of epigenetic metalloenzymes that are
involved in gene transcription and regulation, cell proliferation, differentiation, migration, and …
involved in gene transcription and regulation, cell proliferation, differentiation, migration, and …
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Histone deacetylases (HDACs) play an important role in regulating the expression of genes
involved in tumorigenesis and tumor maintenance, and hence they have been considered …
involved in tumorigenesis and tumor maintenance, and hence they have been considered …
Cu-Catalyzed α-Alkylation of Glycine Derivatives for C(sp3)–H/C(sp3)–H Bond Selective Functionalization
H **ang, Y Ye - ACS Catalysis, 2023 - ACS Publications
Herein, we present the example of Cu-catalyzed oxidation coupling of amino acids/peptides
for producing α-alkylated unnatural glycine derivatives by the activation of double C (sp3) …
for producing α-alkylated unnatural glycine derivatives by the activation of double C (sp3) …